Tiny trial hopes drug can ease liver damage in rare triple condition
NCT ID NCT06144086
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 trial tested a drug called foscenvivint in just 5 people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function scores over 24 weeks. Because the study is very small and early, the results are uncertain but may guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
foscenvivint (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a treatment to improve liver function in people with cirrhosis from HIV/HCV co-infection and hemophilia.
What could go wrong
This is a very small, early-phase trial with only 5 participants, so results may not apply to others. The drug may not improve liver function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, 113-8677, Japan